NUWE Nuwellis, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1506492 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.3%
TTM net income YoY16.9%
TTM EPS YoY197.4%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR—
Margins
Gross margin70.8%
Operating margin-135.8%
Net margin-152.8%
FCF margin-136.6%
EBITDA margin-134.2%
Returns
ROE-200.1%
ROA-128.4%
ROIC (approx.)-815.9%
Asset turnover0.84x
Leverage & solvency
Liabilities / assets26.7%
Debt / equity0.00x
Current ratio3.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-13.6%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.21M | $1.97M | $2.40M | $2.42M | $2.22M | $1.73M | $1.90M | $2.32M |
| Cost of revenue | $674,000 | $471,000 | $719,000 | $770,000 | $772,000 | $767,000 | $837,000 | $967,000 |
| Gross profit | $1.54M | $1.50M | $1.68M | $1.65M | $1.45M | $958,000 | $1.07M | $1.35M |
| R&D expense | $584,000 | $942,000 | $1.73M | $884,000 | $603,000 | $675,000 | $550,000 | $831,000 |
| SG&A expense | $3.01M | $3.73M | $4.52M | $3.21M | $3.54M | $3.19M | $3.58M | $2.91M |
| Operating income | -$2.05M | -$3.17M | -$4.57M | -$2.44M | -$2.70M | -$2.91M | -$3.06M | -$2.39M |
| Pretax income | -$1.97M | -$4.83M | -$4.54M | -$2.42M | $468,000 | -$12.55M | -$3.01M | -$1.47M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $4,000 | $1,000 | $1,000 |
| Net income | -$1.97M | -$4.83M | -$4.54M | -$2.42M | $468,000 | -$12.55M | -$3.01M | -$1.47M |
| EBITDA | -$2.02M | -$3.13M | -$4.53M | -$2.41M | -$2.65M | -$2.86M | -$2.99M | -$2.30M |
| EPS (basic) | -5.81 | -26.64 | -2.19 | — | 177.16 | -2,134.19 | -28.93 | — |
| EPS (diluted) | -5.81 | -26.64 | -2.19 | — | 177.16 | -2,134.19 | -28.93 | — |
| Weighted avg. shares (diluted) | 338,384 | 181,243 | 2.07M | — | 2,646 | 5,881 | 104,142 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $8.29M | $3.92M | $2.08M | $1.08M | $3.09M | $4.45M | $2.56M | $5.09M |
| Receivables | $1.39M | $1.54M | $1.56M | $1.49M | $1.14M | $1.19M | $1.54M | $1.73M |
| Inventory | $1.77M | $1.74M | $1.78M | $1.91M | $2.19M | $2.03M | $1.75M | $1.72M |
| Current assets | $11.93M | $7.90M | $5.83M | $5.19M | $7.20M | $8.42M | $6.12M | $8.86M |
| PP&E, net | $303,000 | $347,000 | $365,000 | $368,000 | $414,000 | $359,000 | $405,000 | $478,000 |
| Intangibles | $93,000 | $102,000 | $112,000 | $0 | — | — | — | — |
| Total assets | $13.45M | $9.13M | $6.96M | $6.12M | $7.98M | $9.20M | $7.01M | $9.86M |
| Current liabilities | $2.99M | $4.01M | $3.73M | $3.03M | $3.52M | $3.89M | $2.75M | $2.56M |
| Total liabilities | $3.59M | $11.17M | $4.29M | $3.49M | $4.07M | $18.16M | $3.42M | $3.33M |
| Shareholders' equity | $9.85M | -$2.06M | $2.66M | $2.62M | $3.91M | -$8.96M | $3.58M | $6.53M |
| Shares outstanding | 540,912 | 574,455 | 2.64M | 5,342 | 1.36M | 527,158 | 4.37M | 104,142 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.98M | -$3.17M | -$3.11M | -$3.03M | -$3.15M | -$2.10M | -$2.54M | -$1.50M |
| Capital expenditure | -$22,000 | $9,000 | $30,000 | -$12,000 | $98,000 | $4,000 | $0 | $23,000 |
| Free cash flow | -$2.96M | -$3.18M | -$3.14M | -$3.02M | -$3.25M | -$2.10M | -$2.54M | -$1.53M |
| Investing cash flow | $22,000 | -$9,000 | -$284,000 | $12,000 | -$98,000 | -$4,000 | $0 | -$23,000 |
| Financing cash flow | $7.33M | $5.02M | $4.39M | $1.05M | $1.89M | $4.00M | $0 | $4.72M |
| Depreciation & amortization | $32,000 | $37,000 | $38,000 | $34,000 | $43,000 | $50,000 | $73,000 | $83,000 |
| Stock-based compensation | $8,000 | $22,000 | $25,000 | $24,000 | $18,000 | $17,000 | $67,000 | $104,000 |
Free plan shows the latest 8 periods; Pro shows all 63 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.